[go: up one dir, main page]

MX2016011881A - Medicamento de peptido en polvo seco. - Google Patents

Medicamento de peptido en polvo seco.

Info

Publication number
MX2016011881A
MX2016011881A MX2016011881A MX2016011881A MX2016011881A MX 2016011881 A MX2016011881 A MX 2016011881A MX 2016011881 A MX2016011881 A MX 2016011881A MX 2016011881 A MX2016011881 A MX 2016011881A MX 2016011881 A MX2016011881 A MX 2016011881A
Authority
MX
Mexico
Prior art keywords
dry
medicament
peptide medicament
powder peptide
powder
Prior art date
Application number
MX2016011881A
Other languages
English (en)
Inventor
Fischer Bernhard
Original Assignee
Apeptico Forschung & Entwicklung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeptico Forschung & Entwicklung Gmbh filed Critical Apeptico Forschung & Entwicklung Gmbh
Publication of MX2016011881A publication Critical patent/MX2016011881A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un medicamento de péptido en polvo seco con una concentración no típica de excipiente de carbohidrato, así como también el medicamento para usarse en tratamiento o prevención de una enfermedad o afección, así como también métodos para fabricar el medicamento.
MX2016011881A 2014-03-18 2015-03-17 Medicamento de peptido en polvo seco. MX2016011881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14160540 2014-03-18
PCT/EP2015/055481 WO2015140125A2 (en) 2014-03-18 2015-03-17 Dry-powder peptide medicament

Publications (1)

Publication Number Publication Date
MX2016011881A true MX2016011881A (es) 2016-12-05

Family

ID=50342194

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011881A MX2016011881A (es) 2014-03-18 2015-03-17 Medicamento de peptido en polvo seco.

Country Status (13)

Country Link
US (1) US10925924B2 (es)
EP (1) EP3062772B1 (es)
JP (1) JP6397984B2 (es)
KR (1) KR102316762B1 (es)
CN (1) CN106456707B (es)
AU (1) AU2015233635B2 (es)
CA (1) CA2940351A1 (es)
DK (1) DK3062772T3 (es)
EA (1) EA034620B1 (es)
ES (1) ES2665180T3 (es)
IL (1) IL247551B (es)
MX (1) MX2016011881A (es)
WO (1) WO2015140125A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3113786B1 (en) * 2014-03-04 2020-02-19 APEPTICO Forschung und Entwicklung GmbH Attenuation of intrapulmonary inflammation
CN106456707B (zh) 2014-03-18 2020-08-11 阿佩普蒂科研究和开发有限责任公司 干粉肽药剂
EP3624885A4 (en) 2017-05-19 2021-03-10 Trudell Medical International EXPIRATORY OVERPRESSURE DEVICE
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
ES2938574T3 (es) 2020-05-08 2023-04-12 Apeptico Forschung & Entwicklung Gmbh Péptido para la prevención o el tratamiento de la COVID-19

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
AU6001094A (en) 1993-02-03 1994-08-29 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
PT877602E (pt) * 1996-01-24 2002-07-31 Byk Gulden Lomberg Chem Fab Processo para o fabrico de composicoes de surfactantes pulmonares em po
EP1264599B1 (en) 1998-08-14 2007-09-26 Rudolf Lucas TNF-derived peptides for use in treating oedema
JP4874522B2 (ja) * 2001-12-05 2012-02-15 サーカッシア リミテッド 免疫療法および系
ATE457736T1 (de) * 2004-08-06 2010-03-15 Nycomed Gmbh Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
RU2409349C2 (ru) 2006-04-14 2011-01-20 Маннкайнд Корпорейшн Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1)
EP2009023A1 (en) 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
EP2397151B1 (en) * 2010-06-21 2015-04-22 Apeptico Forschung Und Entwicklung Gmbh Treatment of vascular complications of diabetes
US9616097B2 (en) * 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
CN106456707B (zh) 2014-03-18 2020-08-11 阿佩普蒂科研究和开发有限责任公司 干粉肽药剂

Also Published As

Publication number Publication date
IL247551B (en) 2019-08-29
CN106456707A (zh) 2017-02-22
EP3062772A2 (en) 2016-09-07
ES2665180T3 (es) 2018-04-24
WO2015140125A2 (en) 2015-09-24
KR20160132021A (ko) 2016-11-16
US20170087207A1 (en) 2017-03-30
US10925924B2 (en) 2021-02-23
EA201691860A1 (ru) 2017-03-31
KR102316762B1 (ko) 2021-10-26
AU2015233635B2 (en) 2019-07-25
AU2015233635A1 (en) 2016-09-15
JP2017510633A (ja) 2017-04-13
IL247551A0 (en) 2016-11-30
CA2940351A1 (en) 2015-09-24
EP3062772B1 (en) 2018-01-24
JP6397984B2 (ja) 2018-09-26
WO2015140125A3 (en) 2016-02-25
EA034620B1 (ru) 2020-02-27
DK3062772T3 (en) 2018-03-26
CN106456707B (zh) 2020-08-11

Similar Documents

Publication Publication Date Title
MX2016011881A (es) Medicamento de peptido en polvo seco.
GB2544906B (en) Devices for treating vestibular and other medical impairments.
MX2022001105A (es) Anticuerpos anti tigit.
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
MY199027A (en) Method for treating or preventing ophthalmological conditions
PH12015502042B1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
PH12017500933A1 (en) Sublingual administration of riluzole
PH12017500747B1 (en) Heterocyclic compound
PH12017500934B1 (en) Sublingual formulation of riluzole
DK3516965T1 (da) A fish feed and method for smoltification and prevention of desmoltification in salmonidae, and for prophylaxis and treatment of haemorrhagic smolt syndrome (hss) in salmonidae
MX2019000677A (es) Células miméticas de células b.
CY1121566T1 (el) Νευροπροστατευτικο και ενδειξη αυτου
MX2018004351A (es) Uso de medicamentos con propiedades neuroprotectoras para prevenir o reducir el riesgo del daño por isquemia-reperfusion en un sujeto.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2016002307A (es) Tratamiento para el cancer.
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
FI20145806A7 (fi) Valmisteet alkoholipunoituksen ja alkoholin indusoimien yliherkkyysreaktioiden hoitamiseksi ja ehkäisemiseksi
MA40574A (fr) Traitement de maladies fibrotiques
JO3333B1 (ar) استعمال 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium أو ملح مقبول دوائيا منه للوقاية من السكري وعلاجه
UA107743C2 (ru) Способ лечения аденокарциномы
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
IN2014DE00818A (es)
IN2013MU03855A (es)